Trial Profile
Interim Results of the Swiss Post Marketing Surveillance Monitoring Quality of Life and Treatment Satisfaction in Patients With Relapsing-Remitting Multiple Sclerosis
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Sep 2014
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms SWISSASCENT
- Sponsors Novartis
- 19 Sep 2014 Status changed from not stated to recruiting.
- 15 Sep 2014 New trial record